FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891520379> ?p ?o ?g. }

• W2891520379 endingPage "1026" @default.
• W2891520379 startingPage "1019" @default.
• W2891520379 abstract "BACKGROUND: The use of novel drug agents in the treatment of multiple myeloma (MM) has been associated with improved therapeutic outcomes and survival; however, MM continues to pose a significant economic burden on patients and health care systems. Evaluating economic implications of therapies can provide key points of distinctions between available treatment options. Patients with MM may experience productivity loss, including lost days from work or inability to work due to MM symptoms or to undergoing treatment. Although direct costs of illness have been well described in the literature, indirect costs associated with MM are understudied. OBJECTIVE: To compare the extent of disability benefit use and resultant workplace productivity loss among U.S. adult patients with newly diagnosed MM who received oral versus injectable MM therapy. METHODS: A retrospective cohort study was conducted using the Truven Health Analytics MarketScan Commercial Claims and Encounters, Medicare Supplemental Coordination of Benefits, and Health and Productivity Management databases (2008-2015). Workplace absenteeism, as measured by disability benefit use, was evaluated 1 year before and 1 year after first MM diagnosis. Patients receiving only oral chemotherapy were compared with those who received injectable therapy. Absenteeism days and associated costs were compared among study groups using multivariable zero-inflated Poisson regression. RESULTS: The final study cohort included 299 patients with newly diagnosed MM, of whom 73 received oral therapy only and 226 received injectable therapy. Treatment type was a significant predictor of disability benefit use. Patients who received injectable therapy missed an average of 110 work days in the 1 year after diagnosis, compared with 87 for patients receiving only oral therapy (difference of 23 days, 95% CI = 19-26, P < 0.001). Treatment type was also a significant predictor of costs associated with lost productivity. Patients who received injectable therapy experienced productivity loss valued at $18,315, compared with patients who only received oral drug therapy ($14,429). The difference between these estimates was statistically significant ($3,886, 95% CI = $3,540-$4,231, P < 0.001). CONCLUSIONS: Patients newly diagnosed with MM face significant losses in productivity. Patients receiving injectable MM therapy use significantly more disability benefits and incur higher productivity costs, compared with those receiving oral MM therapy. Further studies elucidating the nature of the differences between injectable and noninjectable chemotherapy users are needed. DISCLOSURES: This study was funded by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company. Yong and Noga are employees of Millennium Pharmaceuticals. Merola reports personal fees from Millennium Pharmaceuticals during the time of this study." @default.
• W2891520379 created "2018-09-27" @default.
• W2891520379 creator A5045288167 @default.
• W2891520379 creator A5047784168 @default.
• W2891520379 creator A5071159688 @default.
• W2891520379 creator A5085198472 @default.
• W2891520379 date "2018-10-01" @default.
• W2891520379 modified "2023-10-17" @default.
• W2891520379 title "Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy" @default.
• W2891520379 cites W1575390773 @default.
• W2891520379 cites W1633416568 @default.
• W2891520379 cites W1971090026 @default.
• W2891520379 cites W1973683893 @default.
• W2891520379 cites W2000445173 @default.
• W2891520379 cites W2010825039 @default.
• W2891520379 cites W2012874110 @default.
• W2891520379 cites W2020298011 @default.
• W2891520379 cites W2020751391 @default.
• W2891520379 cites W2027191520 @default.
• W2891520379 cites W2048367005 @default.
• W2891520379 cites W2050056063 @default.
• W2891520379 cites W2061326496 @default.
• W2891520379 cites W2067876771 @default.
• W2891520379 cites W2069581014 @default.
• W2891520379 cites W2079244942 @default.
• W2891520379 cites W2134170718 @default.
• W2891520379 cites W2179584783 @default.
• W2891520379 cites W2274511204 @default.
• W2891520379 cites W2278743930 @default.
• W2891520379 cites W2286843233 @default.
• W2891520379 cites W2306484642 @default.
• W2891520379 cites W2336474592 @default.
• W2891520379 cites W2346242965 @default.
• W2891520379 cites W2406890959 @default.
• W2891520379 cites W2460376887 @default.
• W2891520379 cites W2533574559 @default.
• W2891520379 cites W2545983395 @default.
• W2891520379 cites W2560308283 @default.
• W2891520379 cites W2567188480 @default.
• W2891520379 cites W2580485659 @default.
• W2891520379 cites W2592918362 @default.
• W2891520379 cites W2612089043 @default.
• W2891520379 cites W2745820493 @default.
• W2891520379 cites W2766428282 @default.
• W2891520379 cites W4230698388 @default.
• W2891520379 cites W4256343005 @default.
• W2891520379 doi "https://doi.org/10.18553/jmcp.2018.24.10.1019" @default.
• W2891520379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30247101" @default.
• W2891520379 hasPublicationYear "2018" @default.
• W2891520379 type Work @default.
• W2891520379 sameAs 2891520379 @default.
• W2891520379 citedByCount "9" @default.
• W2891520379 countsByYear W28915203792020 @default.
• W2891520379 countsByYear W28915203792021 @default.
• W2891520379 countsByYear W28915203792022 @default.
• W2891520379 countsByYear W28915203792023 @default.
• W2891520379 crossrefType "journal-article" @default.
• W2891520379 hasAuthorship W2891520379A5045288167 @default.
• W2891520379 hasAuthorship W2891520379A5047784168 @default.
• W2891520379 hasAuthorship W2891520379A5071159688 @default.
• W2891520379 hasAuthorship W2891520379A5085198472 @default.
• W2891520379 hasBestOaLocation W28915203791 @default.
• W2891520379 hasConcept C121955636 @default.
• W2891520379 hasConcept C126322002 @default.
• W2891520379 hasConcept C144133560 @default.
• W2891520379 hasConcept C162324750 @default.
• W2891520379 hasConcept C167135981 @default.
• W2891520379 hasConcept C177713679 @default.
• W2891520379 hasConcept C1862650 @default.
• W2891520379 hasConcept C187736073 @default.
• W2891520379 hasConcept C194828623 @default.
• W2891520379 hasConcept C201903717 @default.
• W2891520379 hasConcept C27400517 @default.
• W2891520379 hasConcept C2776364478 @default.
• W2891520379 hasConcept C2908647359 @default.
• W2891520379 hasConcept C6964187 @default.
• W2891520379 hasConcept C71924100 @default.
• W2891520379 hasConcept C72563966 @default.
• W2891520379 hasConcept C73269764 @default.
• W2891520379 hasConcept C99454951 @default.
• W2891520379 hasConceptScore W2891520379C121955636 @default.
• W2891520379 hasConceptScore W2891520379C126322002 @default.
• W2891520379 hasConceptScore W2891520379C144133560 @default.
• W2891520379 hasConceptScore W2891520379C162324750 @default.
• W2891520379 hasConceptScore W2891520379C167135981 @default.
• W2891520379 hasConceptScore W2891520379C177713679 @default.
• W2891520379 hasConceptScore W2891520379C1862650 @default.
• W2891520379 hasConceptScore W2891520379C187736073 @default.
• W2891520379 hasConceptScore W2891520379C194828623 @default.
• W2891520379 hasConceptScore W2891520379C201903717 @default.
• W2891520379 hasConceptScore W2891520379C27400517 @default.
• W2891520379 hasConceptScore W2891520379C2776364478 @default.
• W2891520379 hasConceptScore W2891520379C2908647359 @default.
• W2891520379 hasConceptScore W2891520379C6964187 @default.
• W2891520379 hasConceptScore W2891520379C71924100 @default.
• W2891520379 hasConceptScore W2891520379C72563966 @default.
• W2891520379 hasConceptScore W2891520379C73269764 @default.
• W2891520379 hasConceptScore W2891520379C99454951 @default.

• next